(#26) Real-World Experience with Treatment and Expectations by Satisfaction Status of Persons with Major Depressive Disorder

Abstract: People treated for Major Depressive Disorder (MDD) exhibit varying levels of satisfaction and differing expectations regarding their MDD treatments. This study examines the relationship between self-reported treatment satisfaction and MDD treatment response, experiences, and expectations. A survey was conducted from December 2021 to January 2022, developed in collaboration with mental health experts and patients through the Depression and Bipolar Support Alliance (DBSA). It assessed treatment expectations and experiences among US adults self-reporting MDD. This analysis examined associations between treatment satisfaction and overall experiences. Among 332 respondents receiving MDD treatment, satisfaction levels varied: dissatisfied (n=83; 25%), neutral (n=40; 12%), and satisfied (n=209; 63%). A higher percentage of White individuals were observed in the satisfaction cohort compared to the dissatisfied and neutral cohorts. Significantly fewer satisfied respondents reported chronic fatigue syndrome compared to the other groups. Regardless of satisfaction level, many patients reported severe/very severe MDD symptoms, side effects, moderate to high side effect burden, and work-related issues, with better outcomes observed in the satisfied group. Satisfied respondents reported severe/very severe MDD symptoms (42.6%), ability to complete work (56.5%), presence of side effects (45.9%), moderate to high side effect burden (40.8%), and belief in being on the best treatment (67.5%). Additionally, 82.6% of all respondents desired treatment responses within one week. Key treatment goals included improved functionality, increased interest/pleasure, and reduced feelings of hopelessness, anxiety, and agitation. People with MDD, including those with overall treatment satisfaction, continue to experience unmet treatment needs, particularly regarding symptom control, functioning, side effects, and treatment confidence.Short Description: This study examined treatment satisfaction and experiences with Major Depressive Disorder (MDD) among U.S. adults. A survey (Nf332) assessed satisfaction levels, with 63% satisfied, 12% neutral, and 25% dissatisfied. Despite satisfaction, many experienced severe symptoms, treatment side effects, and work-related issues. All participants desired rapid-onset treatment. Unmet needs remain in managing MDD, particularly in symptom control, side effects, and functionality. Findings highlight the need for improved MDD treatment strategies.Name of Sponsoring Organization(s): Axsome Therapeutics, Inc.